Elevation in Inflammatory Serum Biomarkers Predicts Response to Trastuzumab-Containing Therapy

Approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to trastuzumab-containing therapy. Therefore, there remains an urgent and unmet clinical need for the development of predictive biomarkers for trastuzumab response. Recently, several lines of evidence have demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhateeb, Ahmed A., Leitzel, Kim, Ali, Suhail M., Campbell-Baird, Cynthia, Evans, Matthew, Fuchs, Eva-Maria, Köstler, Wolfgang J., Lipton, Allan, Connor, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530544/
https://www.ncbi.nlm.nih.gov/pubmed/23300545
http://dx.doi.org/10.1371/journal.pone.0051379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530544/
https://www.ncbi.nlm.nih.gov/pubmed/23300545
http://dx.doi.org/10.1371/journal.pone.0051379

Ejemplares similares